Obesity in Focus

BioCentury In Depth

With the first wave of GLP-1 therapies poised to become the biggest blockbusters in biopharma history, the focus turns to what's next in obesity, including combination therapies and new mechanisms to address an improved quality and duration of weight loss and co-morbidities.

Sign up now (free) for access to the featured stories below and put BioCentury to work for you.

Featured Analysis

Complimentary access with registration

ArticleProduct DevelopmentSep 13, 2024

Why GLP-1 is — and isn’t — the next PD-1

GLP-1 may be obesity’s backbone therapy, but the scale of peptide manufacturing challenges is far greater than for PD-1 mAbs

Data GraphicsProduct DevelopmentSep 10, 2024

More contenders enter oral obesity race

But efficacy for oral GLP-1 agonist TERN-601, ecnoglutide still falls short of Roche, Novo

ArticleProduct DevelopmentMar 18, 2024

Treating obesity by quelling inflammation in the brain

How NLRP3 inhibitors could extend durability and enhance CV benefits over GLP-1 therapies alone

More Obesity Analysis from BioCentury

Available to BioCentury Subscribers Only